References
- Brownlee, M., Biochemistry and molecular cell biology of diabetic complications. Nature, 414, 813-820 (2001) https://doi.org/10.1038/414813a
- Buckle, D. R., Cantello, B. C. C., Cawthorne, M. A., Coyle, P. J., Dean, D. K., Faller, A., Haigh, D., Hindley, R. M., Jefcott, L. J., Lister, C. A., Pinto, I. L., Rami, H. K., Smith, D. G., and Smith, S. A., Non-thiazolidinedione antihyperglycemic agents. 2: alpha-carbon substituted beta-phenylpropanoic acids. Bioorg. Med. Chem. Lett., 6, 2127-2130 (1996) https://doi.org/10.1016/0960-894X(96)00382-4
- Cantello, B. C., Cawthorne, M. A., Haigh, D., Hindley, R. M., Smith, S. A., and Thurlby, P., [omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem., 37, 3977-3985 (1994). https://doi.org/10.1021/jm00049a017
- Clark, D. A., Goldstein, S. W., Volkmann, R. A., and Eggler, J. F., Substituted dihydrobenzopyran and dihydrobenzofuran thiazolidine-2,4-diones as hypoglycemic agents. J. Med.Chem., 34, 319-325 (1991) https://doi.org/10.1021/jm00105a050
- DeFronzo, R. A., Bonadonna, R. C., and Ferrannini, E., Pathogenesis of NIDDM. A balanced overview. Diabetes Care, 15, 318-368 (1992) https://doi.org/10.2337/diacare.15.3.318
- Fujita, T., Sugiyama, Y., Taketomi, S., Sohda, T., Kawamatsu, Y., Iwatsuka, H., and Suzuoki, Z., Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy) benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes, 32, 804-810 (1983). https://doi.org/10.2337/diabetes.32.9.804
- Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., and Kliewer, S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem., 270, 12953-12956 (1995) https://doi.org/10.1074/jbc.270.22.12953
- Marcus, A. O., Safety of drugs commonly used to treat hypertension, dyslipidemia, and type 2 diabetes (the metabolic syndrome): part 1. Diabetes Technol. Ther., 2, 101-110 (2000a) https://doi.org/10.1089/152091599316801
- Marcus, A. O., Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2. Diabetes Technol. Ther., 2, 275-285 (2000b) https://doi.org/10.1089/15209150050025258
- Momose, Y., Meguro, K., Ikeda, H., Hatanka, C., Oi, S., and Sohda, T., Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds. Chem. Pharm. Bull., 39, 1440-1445 (1991) https://doi.org/10.1248/cpb.39.1440
- Morral, N., Novel targets and therapeutic strategies for type 2 diabetes. Trends in endocrinology and metabolism, 14, 169-175 (2003) https://doi.org/10.1016/S1043-2760(03)00031-6
- Nuraliev, Iu. N. and Avezov, G. A., The efficacy of quercetin in alloxan diabetes. Eks. Klin. Farmakol., 55, 42-44 (1992)
- Nuss, J. M. and Wagman, A. S., Recent advances in therapeutic approaches to type 2 diabetes, In Annual Reports in Medicinal Chemistry, Doherty, A. M., Ed., Academic Press, San Diego, CA, 35, 211-220 (2000)
- Porte, D., Jr. and Schwartz, M. W., Diabetes complications: why is glucose potentially toxic? Science, 272, 699-700 (1996) https://doi.org/10.1126/science.272.5262.699
- Satyanarayana, N. and Periasamy, M., Hydroboration or hydrogenation of alkenes with cobalt(II) chloride-sodium borohydride. Tetrahedron Lett., 25, 2501-2504 (1984) https://doi.org/10.1016/S0040-4039(01)81215-6
- Shetty, A. K., Rashmi, R., Rajan, M. G. R., Sambaiah, K., and Salimath, P. V., Nutrition Research (New York, NY, United States), 24, 373-381 (2004) https://doi.org/10.1016/j.nutres.2003.11.010
- Shinkai, H., Onogi, S., Tanaka, M., Shibata, T., Iwao, M., Wakitani, K., and Uchida, I., Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents. J. Med. Chem., 41, 1927-1933 (1998) https://doi.org/10.1021/jm970771m
- Sohda, T., Mizuno, K., Imamiya, E., Sugiyama, Y., Fujita, T., and Kawamatsu, Y., Studies on antidiabetic agents. II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4- dione (ADD-3878) and its derivatives. Chem. Pharm. Bull., 30, 3580-3600 (1982) https://doi.org/10.1248/cpb.30.3580
- Varma, S. D., Mizuno, A., and Kinoshita, J. H., Diabetic cataracts and flavonoids. Science, 195, 205-206 (1977) https://doi.org/10.1126/science.401544
- Zimmet, P., Alberti, K. G. M. N., and Shaw, J., Global and societal implications of the diabetes epidemic. Nature, 414, 782 -787(2001) https://doi.org/10.1038/414782a